Vasopressin antagonists in the management of heart failure

References

• Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol.46, 1785–1791 (2005).
   PubMed Web of Science ®Google Scholar
• Adams KF, Fonarow GC, Emerman CL et al; for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalised for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated HEart failure national REgistry (ADHERE). Am. Heart J.149, 209–213 (2005).
   PubMed Web of Science ®Google Scholar
• Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J.144, 1102–1108 (2002).
   PubMed Web of Science ®Google Scholar
• Schrier RW. Role of diminished renal function in cardiovascular mortality. J. Am. Coll. Cardiol.47, 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Butler J, Forman D, Abram W et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am. Heart J.147, 331–338 (2004).
   PubMed Web of Science ®Google Scholar
• Goldsmith SR. Therapeutics in congestive heart failure: from hemodynamics to neurohormones. In: Cardiac Remodeling and Failure. Singh PK, Dixon I, Kirschenbaum LA, Dhalla NS (Eds). Kluwer Academic Publishers, MA, USA 17–34 (2003).
   Google Scholar
• Schrier RW, Gurevich A, Abraham W. Renal sodium excretion, edematous disorders, and diuretic use. In: Renal and Electrolyte Disorders. (6th Edition). Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA 64–114 (2002).
   Google Scholar
• De Luca L, Klein L, Udelson JE et al. Hyponatremia in patients with heart failure. Am. J. Cardiol.96(12A), 19L–23L (2005).
   PubMed Web of Science ®Google Scholar
• Klein L, O’Connor CM, Leimberger JD et al, OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation111(19), 2454–2460 (2005).
   PubMed Web of Science ®Google Scholar
• Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med.305, 263–266 (1981).
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol.1, 1385–1390 (1983).
   PubMed Web of Science ®Google Scholar
• Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Japan Circ. J.32, 745–759 (1968).
   PubMedGoogle Scholar
• Goldsmith SR, Francis GS, Cowley AW, Goldenberg I, Cohn JN. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol.8, 779–783 (1986).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Martin PY. Recent advances in the understanding of water metabolism in heart failure. Adv. Exp. Med. Biol.449, 415–426 (1998).
   PubMed Web of Science ®Google Scholar
• Goldsmith SR. Baroreflex control of vasopressin secretion in normal humans. In: Vasopressin: Cellular and Integrative Functions. Cowley AW, Liard J-F, Ausiello DA (Eds). Raven Press, NY, USA 389–397 (1988).
   Google Scholar
• Sladek JR Jr. Central catecholamine pathways to vasopressin neurons. In: Vasopressin. Schrier RW (Ed.). Raven Press NY, USA 343–352 (1985).
   Google Scholar
• Goldsmith SR.Vasopressin: a therapeutic target in congestive heart failure? J. Card. Fail.5, 347–356 (1999).
   PubMed Web of Science ®Google Scholar
• Jard S. Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int. Suppl.26, S38–S42 (1988).
   Google Scholar
• Xu YJ, Gopalakrishnan V. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res.69, 239–245 (1991).
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor. Eur. J. Pharmacol.391, 39–48 (2000).
   PubMed Web of Science ®Google Scholar
• Arnolda L, McGrath BP, Cocks M, Johnston CI. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J. Clin. Invest.78, 674–679 (1986).
   PubMed Web of Science ®Google Scholar
• Stone CK, Imai N, Thomas A, Sladek CD, Liang CS, Hood WB. Hemodynamic effects of vasopressin inhibition in congestive heart failure. Clin. Res.34, 632A (1986).
   Google Scholar
• Naitoh M, Suzuki H, Murakami M et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am. J. Physiol.267, H2245–H2254 (1994).
   PubMed Web of Science ®Google Scholar
• Serradeil-Ledel C, Wagon J, Garcia G et al. Biochemical and pharmacologic properties of SR 49059, a new potent nonpeptide antagonist of rat and human vasopression V1 receptors. J. Clin. Invest.92, 224–231 (1993).
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation104, 2417–2423 (2001).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O’Connor CM et al, for the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA291, 1963–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation107, 2690–2696 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson RJ. Hospital associated hyponatremia. Kidney Int.29, 1237–1247 (1986).
   PubMed Web of Science ®Google Scholar
• Chin MW, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch. Intern. Med.156, 1814–1820 (1996).
   PubMed Web of Science ®Google Scholar
• Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting enzyme inhibition in patients with severe chronic heart failure. Circulation73, 257–267 (1986).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M et al; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med.355(20), 2099–2112 (2006).
   PubMed Web of Science ®Google Scholar
• Wong F, Blei AT, Blendis LM et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology37, 182–191 (2003).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Adams K, O’Connor C et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin antagonist in Chronic Heart Failure (ACTIV in CHF) trial. J. Am. Coll. Cardiol.145A (2005) (Abstract).
   Google Scholar
• Gheorghiade M, Orlandi C, Burnett JC et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card. Fail.11, 260–269 (2005).
   PubMed Web of Science ®Google Scholar
• Russell SD, Selaru P, Pyne DA et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin Antagonist in CHF patients undergoing Exercise) trial. Am. Heart J.145, 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gurevich AK, Abraham WT. Renal sodium excretion, edematous disorders, and diuretic use. In: Renal and Electrolyte Disorders (6th Edition). Schrier RW (Ed.). Lippincott Williams and Wilkins, PA, USA 72–73 (2003).
   Google Scholar
• Gottlieb S, Skettino SL, Wolff A et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am. Coll. Cardiol.35, 56–59 (2000).
   PubMed Web of Science ®Google Scholar
• Aronson D. Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure. Presented at: American College of Cardiology 2004 Scientific Sessions New Orleans, LA, USA, 7–10 March, 2004.
   Google Scholar
• Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol.43, 61–67 (2004).
   PubMed Web of Science ®Google Scholar
• Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am. Heart J.138, 285–290 (1999).
   PubMed Web of Science ®Google Scholar
• Hillege HL, Girbes, AR, de Kam P et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation102, 203–210 (2000).
   PubMed Web of Science ®Google Scholar
• Costanzo MR. Chronic diuretics, renal dysfunction raise mortality risk in decompensated heart failure. Presented at: American College of Cardiology 2004 Scientific Sessions New Orleans, LA, USA, 7–10 March, 2004.
   Google Scholar
• Cooper HA, Dries DL, Davis CE et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation100, 1311–1315 (1999).
   PubMed Web of Science ®Google Scholar